Salugen Biosciences 's clinical studies will continue to evaluate the role of laboratory testing in the optimization of pain management.
The following outlines some of the studies that Salugen Biosciences has planned:
|
Product:
|
HAVEOS Genetics Abuse Panel
|
|
Type of Study:
|
R.A.C.E.R. Study - Retrospective Analysis of Clinical and Economic Results of HAVEOS Genetics Abuse Testing in Suspected Opioid Abusers
18-month observational trial
Currently enrolling
|
|
Estimated Begin/End Date:
|
January 2010 to June 2011
|
|
Projected Measurements:
|
-
200 patients genotyped to demonstrate association with opioid addiction
-
Genetic analysis of 12 genes in panel
-
Pharmacoeconomic evaluation of cost-savings
|
|
Product:
|
HAVEOS Genetics Abuse Panel
|
|
Type of Study:
|
Evaluation of response to therapy based on genotype
Currently enrolling
|
|
Estimated Begin/End Date:
|
End date of July 2011
|
|
Projected Measurements:
|
Visual analog scale (1-5) of patient response to therapy based on genotype
|
|
Product:
|
DOLORMED
|
|
Type of Study:
|
Genotype association with clinical efficacy
Currently enrolling
|
|
Estimated Begin/End Date:
|
July 2011 to December 2011
|
|
Projected Measurements:
|
Genotype compared to visual analog scale of clinical efficacy of opioid pain medication
|
|
Product:
|
PEDEMED and HAVEOS Genetics
|
|
Type of Study:
|
Observational study comparing urine drug testing to genotype |
|
Estimated Begin/End Date:
|
July 2011 to December 2011
|
|
Projected Measurements:
|
Evaluation of drug excretion and metabolites versus genetics
Evaluation of genetics and abuse of illegal drugs |
